Oncolytics Biotech
ONCY
$1.19
Share price
0.85%
Change (1 day)
-30.41%
Change (1 year)
Categories
Oncolytics Biotech (ONCY) - P/B ratio
P/B ratio as of May 2024 : 4.31
According to Oncolytics Biotech
's latest financial reports the company has a price-to-book ratio of 4.31.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Oncolytics Biotech - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 4.77 | -2.88% |
| 2022-12-31 | 4.91 | 84.2% |
| 2021-12-31 | 2.67 | -49.52% |
| 2020-12-31 | 5.28 | -100.29% |
| 2019-12-31 | < -1000 | -26127.89% |
| 2018-12-31 | 7.05 | -41.6% |
| 2017-12-31 | 12.1 | 303.35% |
| 2016-12-31 | 2.99 | 62.41% |
| 2015-12-31 | 1.84 | -57.43% |
| 2014-12-31 | 4.33 | -31.67% |
| 2013-12-31 | 6.34 | -69.38% |
| 2012-12-31 | 20.7 | 114.34% |
| 2011-12-31 | 9.65 | -11.45% |
| 2010-12-31 | 10.9 | 101.03% |
| 2009-12-31 | 5.42 | -20.52% |
| 2008-12-31 | 6.82 | 107.39% |
| 2007-12-31 | 3.29 | 10.83% |
| 2006-12-31 | 2.97 | -32.93% |
| 2005-12-31 | 4.43 | -3.44% |
| 2004-12-31 | 4.58 | -5.57% |
| 2003-12-31 | 4.85 | 126.63% |
| 2002-12-31 | 2.14 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Eli Lilly LLY | 57.3 | 1,229.50% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 5.39 | 25.14% | 🇺🇸 USA |
 Mirati Therapeutics MRTX | 4.35 | 0.92% | 🇺🇸 USA |
 Aeterna Zentaris AEZS | 0.5357 | -87.57% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 1.94 | -54.90% | 🇮🇱 Israel |
 AVEO Oncology
AVEO | 18.1 | 319.34% | 🇺🇸 USA |